文献速递血液透析通路

终末期肾病早期穿刺型动静脉移植物两年结局

Two-Year Outcomes of Early Cannulation Arteriovenous Grafts for End-Stage Renal Disease.
PubMed 文献 · Ann Vasc Surg · 2019-04-19

该研究追踪397例序贯透析通路创建患者,比较动静脉内瘘(AVF)与早期穿刺型动静脉移植物(ECAVG)的并发症、再干预、住院结局与费用。1年时ECAVG组费用更低、通畅率与生存率更优、导管天数与并发症更少。

要点

  • 1年总费用AVF为17523美元,ECAVG为5894美元(P<0.01)。
  • 1年一期辅助通畅率AVF 49.3% vs ECAVG 81.4%(P=0.027)。
  • ECAVG组导管天数、并发症及二次干预均少于AVF组。

核心结论

  • ECAVG较AVF在1年时总费用更低且临床结局更优。
  • 以ECAVG为核心的紧急起始透析通路项目可能有助于实现更低成本更好的医疗。

研究设计与样本

  • 131例接受AVF,266例接受ECAVG,追踪至术后2年。

主要发现

  • 1年总费用AVF为17523美元,ECAVG为5894美元(P<0.01)。
  • 1年一期辅助通畅率AVF 49.3% vs ECAVG 81.4%(P=0.027)。
  • 1年二期辅助通畅率AVF 63.8% vs ECAVG 85.4%(P=0.011)。
  • 1年生存率AVF 78.6% vs ECAVG 85.0%(P=0.034)。
  • ECAVG组导管天数2.3% vs AVF 19.1%(P<0.001),并发症1.6% vs 21.5%(P<0.001),二次干预17.0% vs 52.5%(P<0.001)。

临床怎么用

  • 对需紧急起始透析的ESRD患者,可优先考虑ECAVG以减少导管使用及相关并发症。
  • ECAVG可能降低总体医疗费用并改善1年通畅率与生存率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Almost 80% of patients with end-stage renal disease (ESRD) initiate dialysis via a central venous catheter (CVC). CVCs are associated with multiple complications and a high cost of care. The purpose of our project is to determine the impact of early cannulation arteriovenous grafts (ECAVGs) on quality of care and costs. METHODS: The dialysis access modality, complications, secondary interventions, hospital outcomes, and detailed costs were tracked for 397 sequential patients who underwent access creation between July 2014 and October 2018. Complications were grouped into deep vein thrombosis, line infections, sepsis, pneumothorax, and other. Secondary interventions included angioplasty, angioplasty and stent grafting, thrombectomy, surgical revision, and explantation. Hospital outcomes included length of stay, inpatient mortality, 30-day readmission, and discharge disposition. Costs included supplies, medications, laboratory tests, labor, and other direct costs. All variables were measured at the time of the index procedure, 30 days, 90 days, 180 days, 270 days, 1 year, 18 months, and 2 years. RESULTS: There were 131 patients who underwent arteriovenous fistula (AVF) and 266 who received ECAVG for dialysis access. The total cost of care per patient was $17,523 for AVF and $5,894 for ECAVG at 1 year (P < 0.01). Primary-assisted patency for AVF was 49.3% versus 81.4% for ECAVG (P = 0.027), and secondary-assisted patency for AVF was 63.8% versus 85.4% for ECAVG at 1 year (P = 0.011). There was a survival advantage for ECAVGs at 1 year (78.6% for AVF vs 85.0% for ECAVG, P = 0.034). Patients who received ECAVG had fewer CVC days (2.3% vs 19.1% for AVF, P < 0.001), fewer complications (1.6% vs. 21.5% for AVF, P < 0.001), and fewer secondary interventions (17.0% vs 52.5% for AVF, P < 0.001). CONCLUSIONS: This is the first study on patients with ESRD to report detailed outcomes and cost analysis as it relates to AVF versus ECAVG. ECAVGs have an advantage over AVFs due to lower overall cost and better clinical outcomes at 1 year. Implementation of an urgent start dialysis access program centered around ECAVGs may help achieve the national goal of better health care at a lower cost for patients with ESRD.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Desai SS. Two-Year Outcomes of Early Cannulation Arteriovenous Grafts for End-Stage Renal Disease. Ann Vasc Surg. 2019. PMID: 31009720. doi:10.1016/j.avsg.2019.02.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。